Randomized controlled trials do not support efficacy of any of the tested doses of fluvoxamine in prevention of disease progression in adults with incipient non-severe COVID-19 disease: a case-study systematic review and meta-analysis

Abstract excerpt

<h4>Background</h4> Recent meta-analyses of randomized controlled trials (RCTs) claimed efficacy of higher-dose fluvoxamine (2 x 100 mg/day, as opposed to 2 x 50 mg/day) in prevention of disease deterioration in adults with mild - moderate COVID-19 disease. <h4>Objectives</h4> Investigate whether such claims are supported by the data. <h4>Methods</h4> Systematic review and meta-analysis of RCTs evaluating highe...

Topics

Open a Topic to create a Post that cites this publication.

• Biosensing Techniques
• COVID-19 Drug Treatment
• COVID-19 Vaccines
• Dexamethasone
• Glucocorticoids
• Molecular Diagnostic Techniques
• Nucleic Acid Amplification Techniques
• World Health Organization

Identifiers and source

Literature Corpus work

6ad9a6e4-19b2-55fb-83ae-7a77eaaadba6

DOI

10.64898/2026.04.01.26349972